Literature DB >> 8149496

Five of six protein kinase C isoenzymes present in normal mucosa show reduced protein levels during tumor development in the human colon.

P Kahl-Rainer1, J Karner-Hanusch, W Weiss, B Marian.   

Abstract

Protein kinase C (PKC) isoenzyme patterns were analyzed from human colonic epithelial cells of normal, premalignant and malignant origin. PKCs alpha, beta and zeta were found predominantly in the cytosol and the subtypes delta, epsilon and neta almost exclusively in the particulate fraction. Of the isoenzymes found beta, epsilon and neta were low in abundance and could only be detected after partial purification of cellular fractions on DE52-cellulose. Only PKC beta was similar in abundance in normal mucosa, premalignant and malignant colonic epithelial cells, while all other isoenzymes were decreased in abundance in tumor cells. The loss of PKC protein in tumor cells correlated with a loss in enzyme activity, as has been described before by other groups, especially affecting the Ca(2+)-dependent isoenzymes. On the other hand, activation of PKC by phorbol ester treatment in vivo was only possible in carcinoma cells (4/4) and a subset of adenomas (3/7). Normal human colonic epithelial cells did not respond to TPA treatment with either stimulation of PKC activity or translocation of cytosolic enzymes to the particulate fraction. Instead, TPA treatment resulted in a rapid loss of protein for the isoenzymes alpha, delta and to a lesser degree also beta. We assume that this reflects qualitative differences in response between normal and tumor cells, that may be due to the differences in isoenzyme distribution.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8149496     DOI: 10.1093/carcin/15.4.779

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  9 in total

1.  Protein kinase Cα signaling regulates inhibitor of DNA binding 1 in the intestinal epithelium.

Authors:  Fang Hao; Marybeth A Pysz; Kathryn J Curry; Kristin N Haas; Steven J Seedhouse; Adrian R Black; Jennifer D Black
Journal:  J Biol Chem       Date:  2011-03-18       Impact factor: 5.157

Review 2.  The Dual Roles of the Atypical Protein Kinase Cs in Cancer.

Authors:  Miguel Reina-Campos; Maria T Diaz-Meco; Jorge Moscat
Journal:  Cancer Cell       Date:  2019-08-29       Impact factor: 31.743

Review 3.  Multifunctional roles of PKCδ: Opportunities for targeted therapy in human disease.

Authors:  Mary E Reyland; David N M Jones
Journal:  Pharmacol Ther       Date:  2016-05-11       Impact factor: 12.310

4.  Differential effects of deoxycholic acid on proliferation of neoplastic and differentiated colonocytes in vitro.

Authors:  L P Peiffer; D J Peters; T J McGarrity
Journal:  Dig Dis Sci       Date:  1997-11       Impact factor: 3.199

5.  PKCalpha tumor suppression in the intestine is associated with transcriptional and translational inhibition of cyclin D1.

Authors:  Marybeth A Pysz; Olga V Leontieva; Nicholas W Bateman; Joshua M Uronis; Kathryn J Curry; David W Threadgill; Klaus-Peter Janssen; Sylvie Robine; Anna Velcich; Leonard H Augenlicht; Adrian R Black; Jennifer D Black
Journal:  Exp Cell Res       Date:  2009-02-14       Impact factor: 3.905

Review 6.  Aberrant crypt foci as microscopic precursors of colorectal cancer.

Authors:  Lei Cheng; Mao-De Lai
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

7.  Extracellular pressure stimulates colon cancer cell proliferation via a mechanism requiring PKC and tyrosine kinase signals.

Authors:  M F Walsh; R K-Y Woo; R Gomez; M D Basson
Journal:  Cell Prolif       Date:  2004-12       Impact factor: 6.831

Review 8.  The complexities of PKCα signaling in cancer.

Authors:  Adrian R Black; Jennifer D Black
Journal:  Adv Biol Regul       Date:  2020-11-23

Review 9.  Targeting Protein Kinase C Downstream of Growth Factor and Adhesion Signalling.

Authors:  Catríona M Dowling; Patrick A Kiely
Journal:  Cancers (Basel)       Date:  2015-07-15       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.